Employers and well-being experts will address how to achieve workplace well-being through collaboration at annual Health Enhancement Research Organization Forum

Yardley, Pa. (August 29, 2019) StayWell announced today that it has signed on as an official sponsor of HEROForum19, “Thriving Organizations: Achieving Well-Being Through Collaboration,” which takes place Sept. 10-12 in Portland, OR. An annual event hosted by the Health Enhancement Research Organization (HERO), the Forum brings together health and well-being professionals to network, share knowledge, and learn from top experts in the industry.

More than 500 employers, employee health and well-being providers, wellness industry professional organizations, and research experts are expected to attend Forum19 to discuss the need for collaboration within organizations, across disciplines and industries, and how this contributes to well-being outcomes and the ability to create thriving workplaces. The prestigious C. Everett Koop Award and HERO Workplace Health and Well-Being Awards will also be presented during the annual gathering.

“Learning, like well-being, doesn’t happen in a vacuum. When we break down silos within organizations and across the broader marketplace, we can learn from the experiences of others. This level of open dialogue is a trademark of the HERO Forum,” said Karen Moseley, president of HERO. “Forum19 will highlight partnerships that have defied traditional boundaries and showcase leaders, organizations and experts who believe that healthy cultures are prerequisites to helping individuals and communities thrive. The incredible support of StayWell is key to making Forum a success each year, and we are beyond thankful for their commitment to employee health and well-being.”

“We’re excited to be a sponsor for HERO Forum19 and join with other organizations to collaborate and present new ideas in the evolution of employee health and well-being solutions, said Nicole Latimer, CEO of StayWell.  “StayWell continues to present new workplace wellness solutions through innovative research and investments, helping to drive the industry forward in advanced well-being programs for employers and their employees.”

As a leader in workplace well-being programs, StayWell applies proven strategies in behavioral science to drive long-term change and supports these efforts with technology to empower users to take an active role in their health. This approach includes a digital health platform; on-site staff solutions; in-person, telephonic, and virtual health coaching for individuals and groups; health assessments, biometric screenings, fitness tracking devices, and custom reporting; virtual reality wellness application; wellness incentive designs; and comprehensive employee communication and engagement campaigns.

Registration and additional details about the HERO Forum19 can be found online at https://forum.hero-health.org/, or by calling HERO at 952-835-4257.


For more information:

Barbara Tabor, HERO / (+1 651-450-1342) / barbara@taborpr.com

About StayWell

StayWell is a health empowerment company that enables populations to improve health outcomes through the science of behavior change. For more than 40 years, the company has been a pioneer in employer well-being and patient education solutions that lower risks and reduce costs. StayWell has earned numerous top industry honors for its population health programs, including the C. Everett Koop National Health Award and the Web Health Award. The company has also received Utilization Review Accreditation Committee (URAC) and National Committee for Quality Assurance (NCQA) accreditation for several of its programs. StayWell is majority-owned by Healthcare Services & Solutions, LLC, a wholly owned subsidiary of Merck & Co., Inc. The company is headquartered in Yardley, Pa., with additional locations including St. Paul, Minn. and Portland, Ore. To learn more, visit www.staywell.com or connect with StayWell on Twitter, Facebook or LinkedIn.

About Merck

For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola. For more information, visit www.merck.com and connect with us on Twitter, Facebook, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of The StayWell Company, a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forwardlooking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2018 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

About Vestar Capital Partners

Vestar Capital Partners is a leading U.S. middle-market private equity firm specializing in management buyouts and growth capital investments. Vestar invests and collaborates with incumbent management teams and private owners to build long-term enterprise value, with a focus on Consumer, Healthcare, and Business Services & Industrial Products. Since its founding in 1988, Vestar funds have completed more than 80 investments in companies – as well as more than 200 add-on acquisitions – with a total value of approximately $50 billion. For more information, please visit www.vestarcapital.com.

About HERO – Based in Waconia, MN, HERO (the Health Enhancement Research Organization) is a not-for-profit, 501(c)3 corporation that was established in 1997. HERO is dedicated to identifying and sharing best practices that improve the health and well-being of employees, their families, and communities. To learn more, visit www.hero-health.org. Follow us on Twitter @heroehm, Facebook, or LinkedIn.

Media Contact / Denise Spillane / 215.760.9144